关于：舒尼替尼单药治疗或肾切除术后治疗转移性肾细胞癌 - Suppr

Suppr

超能文献

Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma.

作者信息

Staehler Michael, Battle Dena, Bex Axel, Hammers Hans, George Daniel

机构信息

University of Munich, Department of Urology, Multidisciplinary Center on Renal Tumors, Munich, Germany.

Kidney Cancer Research Alliance KCCure, VA, USA.

出版信息

Eur Urol. 2018 Dec;74(6):842-843. doi: 10.1016/j.eururo.2018.08.011. Epub 2018 Aug 28.

DOI:10.1016/j.eururo.2018.08.011

PMID:30170873

Abstract

摘要

相似文献

Re: Sunitinib Alone or after Nephrectomy in Metastatic Renal-cell Carcinoma.关于：舒尼替尼单药治疗或肾切除术后治疗转移性肾细胞癌

Eur Urol. 2018 Dec;74(6):842-843. doi: 10.1016/j.eururo.2018.08.011. Epub 2018 Aug 28.

Re: Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma.关于：舒尼替尼单药治疗或肾切除术后用于转移性肾细胞癌

Eur Urol. 2019 May;75(5):876-877. doi: 10.1016/j.eururo.2019.02.018. Epub 2019 Feb 28.

Re: Arnaud Méjean, Alain Ravaud, Simon Thezenas, et al. Sunitinib Alone or After Nephrectomy in Metastatic Renal-cell Carcinoma. N Engl J Med 2018;379:417-27: CARMENA Trial: Is This the End of Cytoreductive Nephrectomy in Patients with Clear-cell Renal Cell Carcinoma?回复：阿诺·梅让、阿兰·拉沃德、西蒙·泰泽纳斯等。舒尼替尼单药治疗或肾切除术后治疗转移性肾细胞癌。《新英格兰医学杂志》2018年；379:417 - 27：CARMENA试验：这是否意味着透明细胞肾细胞癌患者减瘤性肾切除术的终结？

Eur Urol Oncol. 2019 May;2(3):340-341. doi: 10.1016/j.euo.2018.08.002. Epub 2018 Aug 24.

Has the Age of Cytoreductive Nephrectomy Come to an End?: Commentary on: Sunitinib Alone or After Nephrectomy in Metastatic Renal-Cell Carcinoma.减瘤性肾切除术的时代已经结束了吗？：对《舒尼替尼单药治疗或肾切除术后治疗转移性肾细胞癌》的评论

Urology. 2018 Nov;121:1-2. doi: 10.1016/j.urology.2018.07.007. Epub 2018 Aug 2.

Sunitinib and Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma.舒尼替尼与减瘤性肾切除术治疗转移性肾细胞癌

J Urol. 2019 Mar;201(3):453-454. doi: 10.1016/j.juro.2018.09.050.

Editorial Comment: Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib: The SURTIME Randomized Clinical Trial.编者按：接受舒尼替尼治疗的同步转移性肾细胞癌患者中即刻与延迟减瘤性肾切除术的比较：SURTIME随机临床试验

Int Braz J Urol. 2020 May-Jun;46(3):476. doi: 10.1590/S1677-5538.IBJU.2020.03.12.

Cytoreductive nephrectomy in metastatic renal cancer - less is more.转移性肾癌的减瘤性肾切除术——少即是多。

Nat Rev Clin Oncol. 2018 Oct;15(10):595-596. doi: 10.1038/s41571-018-0065-4.

Cytoreductive Nephrectomy in Metastatic Renal Cell Cancer: Not All That It's Cut Out to Be.转移性肾细胞癌中的减瘤性肾切除术：并非如其所宣称的那样。

JAMA Oncol. 2019 Feb 1;5(2):171-172. doi: 10.1001/jamaoncol.2018.5503.

The outcome of patients treated with sunitinib prior to planned nephrectomy in metastatic clear cell renal cancer.舒尼替尼治疗计划肾切除术的转移性透明细胞肾细胞癌患者的结局。

Eur Urol. 2011 Sep;60(3):448-54. doi: 10.1016/j.eururo.2011.05.028. Epub 2011 May 17.

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.辅助舒尼替尼治疗肾切除术后高危肾细胞癌。

N Engl J Med. 2016 Dec 8;375(23):2246-2254. doi: 10.1056/NEJMoa1611406. Epub 2016 Oct 9.

引用本文的文献

Do Metastatic Kidney Cancer Patients Benefit From Cytoreductive Nephrectomy? A Real-World Retrospective Study From the SEER Database.转移性肾癌患者能从减瘤性肾切除术中获益吗？一项基于监测、流行病学和最终结果（SEER）数据库的真实世界回顾性研究。

Front Surg. 2021 Aug 30;8:716455. doi: 10.3389/fsurg.2021.716455. eCollection 2021.

Sequential Treatment Based on Sunitinib and Sorafenib in Patients with Metastatic Renal Cell Carcinoma.基于舒尼替尼与索拉非尼的序贯治疗转移性肾细胞癌患者

Cureus. 2019 Mar 13;11(3):e4244. doi: 10.7759/cureus.4244.

Current Status of Immunotherapy for Localized and Locally Advanced Renal Cell Carcinoma.局限性和局部进展期肾细胞癌免疫治疗的现状

J Oncol. 2019 Apr 1;2019:7309205. doi: 10.1155/2019/7309205. eCollection 2019.

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验